Sino Biopharmaceutical (1177.HK) — Annual Report 2025, ESG & Sustainability PDFs

Sino Biopharmaceutical

1177.HK

Sino Biopharmaceutical is a Specialty Chemicals company in the Healthcare sector, headquartered in HKG. This page tracks verified corporate disclosures including annual reports, ESG reports, sustainability filings, and financial statements.

The latest annual report from Sino Biopharmaceutical tracked by Report Scout is the 2025 annual report. In total, Report Scout tracks 4 verified Sino Biopharmaceutical reports (2024–2025), with verified links to the official PDF documents.

Subscribe to alerts for Sino Biopharmaceutical

Most Recent Report

Sino Biopharmaceutical 2025 Annual

Download Sino Biopharmaceutical 2025 Annual PDF

Reports

4 total

Available reports

Annual reports, ESG disclosures, sustainability reports, financial filings, and other corporate documents published by Sino Biopharmaceutical.

YEARS

2025

2 reports

Annual

Sino Biopharmaceutical Annual 2025

Sino Biopharmaceutical 2025 Annual PDF

ESG

Sino Biopharmaceutical ESG 2025

Published 2026-04-29

Sino Biopharmaceutical 2025 ESG PDF Sino Biopharmaceutical 2025 ESG Web Page

2024

2 reports

ESG

Sino Biopharmaceutical ESG 2024

Published 2025-04-29

Sino Biopharmaceutical 2024 ESG PDF Sino Biopharmaceutical 2024 ESG Web Page

Annual

Sino Biopharmaceutical Annual 2024

Published 2025-04-29

Sino Biopharmaceutical 2024 Annual PDF

FAQ

Frequently asked questions

When was Sino Biopharmaceutical's latest annual report published?

The most recent annual report from Sino Biopharmaceutical tracked by Report Scout is the 2025 annual report. New filings are added automatically once discovered and verified.

Where can I download Sino Biopharmaceutical's reports as PDF?

This page lists 4 verified Sino Biopharmaceutical reports (2024–2025) with direct links to the official PDF documents published by the company.

Does Report Scout track Sino Biopharmaceutical's sustainability and ESG reports?

Yes. Report Scout tracks 2 sustainability-related reports from Sino Biopharmaceutical — the most recent is the 2025 ESG report.